Recruiting soon

SCOOP-RNPCImpact of RNPC Weight Loss Program on Overweight/Obese Patients' Health and Comorbidities

Study Aim

This observational study aims to evaluate the effectiveness of the national RNPC weight reduction program in overweight/obese individuals, by observing changes in their treatments or improvements in related health conditions such as arterial hypertension, glucose intolerance, and type 2 diabetes, after a minimum of 6 months but not exceeding one year.

What is being collected

Data Collection

Collected from today forward - Prospective

Who is being recruted

Apnea+24

+ Body Weight

+ Cardiovascular Diseases

From 18 to 85 Years

+14 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.

Observational

Study Start: July 2023

See protocol details

Summary

Principal SponsorGroupe Éthique et Santé

Study ContactOdile Fabre, PharmD, PhDMore contacts

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: July 15, 2023

Actual date on which the first participant was enrolled.

This study focuses on the French RNPC weight reduction program, designed for overweight or obese individuals. The main goal is to understand if this program can lead to medium-term health benefits for these patients. The research aims to show that the RNPC program can reduce the need for drug or instrumental treatments, such as continuous positive pressure ventilation used for sleep apnea, and improve health conditions related to being overweight or obese. The study involves around 10,000 participants who will be followed for 5 years, contributing to a better understanding of the impact of weight loss on various aspects of health and well-being. Participants in this study will follow the standard nutritional care provided by the RNPC program. The study will collect clinical and biological data, along with self-reported questionnaires completed by the participants. The primary outcome being measured is the number of participants who see a change in their initial drug and/or instrumental treatment, or a disappearance of health conditions related to being overweight or obese. These conditions may include, but are not limited to, high blood pressure, type 2 diabetes, obstructive sleep apnea, depression, and pain. The changes will be evaluated at the end of the program, which lasts a minimum of 6 months but no longer than one year.

Official TitleAssessment of the Impact of Short, Medium and Long-term Weight Loss, Obtained by a Standardized Nutritional and Psycho-Behavioral Rehabilitation Program (RNPC Program) and in Real Life Conditions, in Obese or Overweight Patients

NCT05857319

Principal SponsorGroupe Éthique et Santé

Study ContactOdile Fabre, PharmD, PhDMore contacts

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

10000 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 85 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

ApneaBody WeightCardiovascular DiseasesDiabetes MellitusDiabetes Mellitus, Type 2Digestive System DiseasesEndocrine System DiseasesFatty LiverLiver DiseasesMetabolic DiseasesNervous System DiseasesNutrition DisordersNutritional and Metabolic DiseasesObesityRespiration DisordersRespiratory Tract DiseasesSigns and SymptomsSleep Apnea SyndromesSleep Wake DisordersPathological Conditions, Signs and SymptomsSleep Apnea, ObstructiveSleep Disorders, IntrinsicDyssomniasOvernutritionGlucose Metabolism DisordersOverweightNon-alcoholic Fatty Liver Disease

Criteria

4 inclusion criteria required to participate

Body Mass Index (BMI) greater than or equal to 25 kg/m² and/or waist circumference greater than or equal to 80 cm in women and 94 cm in men;

Possessing a personal smartphone;

Subjects able to sign the informed consent.

Subjects subject to the French health system;

10 exclusion criteria prevent from participating

Person deprived of liberty by judicial or administrative decision;

Person subject to a legal protection measure, who cannot be included in clinical trials;

Persons refusing to sign the participation consent;

People with an electrical medical device such as a pacemaker, battery, insulin pump or cochlear implant;

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has no location dataSave this study to your profile to know when the location data is available.

Recruiting soonNo study centers